DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Meniere disease — screening already-approved drugs against its 38-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMeniere disease maps to a 38-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for meniere disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
SET and mariner transposase domain methyltransferase (SETMAR) — SETMAR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet sahdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3BO5 · 1.59 Å · ligand S-ADENOSYL-L-HOMOCYSTEINE (SAH). Experimental structure, not a prediction.
What the evidence adds up to
A 2019 systematic review and meta-analysis of sixteen trials examined device therapy for Meniere's disease and reported improved vertigo control, with a reduction in vertigo days per month (weighted mean difference 3.15, 95% CI 2.00-4.31), vertigo episodes per month (WMD 7.37, 95% CI 2.40-12.35), and vertigo visual analogue scores (WMD 41.51, 95% CI 34.68-48.34). The overall complete vertigo control (class A) rate was 50% (95% CI 37%-64%). The therapy also reduced sick days per month (WMD 4.56, 95% CI 2.15-6.97), improved functional level (WMD 2.66, 95% CI 2.15-3.17), and showed benefit for hearing changes (WMD 3.19, 95% CI 0.66-5.71), with no publication bias detected.
A 2013 prospective, randomised, double-blind, double-dummy, multicentre, parallel-group study compared extended-release nimodipine 90 mg once daily with conventional nimodipine 30 mg three times daily in patients with peripheral vertigo. In the extended-release group, the vertigo severity index decreased by 50% in 24% of patients at 14 days, 41% at 4 weeks, and 89% at 8 weeks; the vestibular disability index decreased by 50% in 24% of patients at 15 days, 83% at 4 weeks, and 92% at 8 weeks. In the conventional group, the vertigo severity index decreased by 50% in 17% of patients at 14 days, 41% at 4 weeks, and 90% at 8 weeks; the vestibular disability index decreased by 50% in 17% at 15 days, 53% at 4 weeks, and 64% at 8 weeks. The authors concluded both products were effective and well tolerated, with no difference between groups.
A 2012 Polish study of kinesitherapy in 35 patients with mixed-type vertigo reported improvements after two months of individually selected habituation and corrective exercises. Mean labyrinthine excitability fell from 25.38 degrees/s before rehabilitation to 22.26 degrees/s after; absolute directional preponderance fell from 7.62 to 1.92 degrees/s, relative directional preponderance from 31.36 to 12.57 degrees/s, and unilateral deficit from 32.12 to 14.34 degrees/s. Subjective vertigo intensity on a 5-stage scale fell from 3.85 points at baseline to 2.91 after two weeks, 2.35 after one month, and 1.2 after two months. The authors called kinesitherapy an alternative and very effective method.
A 2019 literature review of surgical procedures for intractable Meniere disease noted that although individual papers report good results, there have been few well-designed clinical studies with control groups or long-term observation regarding vertigo control and hearing preservation. Surgery can damage the ipsilateral ear, and contralateral hearing is often suboptimal. A 2025 review describes Meniere disease as a heterogeneous condition with distinct subtypes driven by different mechanisms, including endolymphatic hydrops, immune dysregulation, genetic predisposition, vascular dysfunction, and viral infection. A 1989 overview of dizziness states that most vertigo is caused by self-limiting peripheral vestibular disorders, with treatment directed at controlling acute autonomic symptoms and labyrinthine suppression until compensation occurs. What remains missing is robust evidence from controlled, long-term trials that stratify patients by disease subtype, and a clear understanding of which interventions—device, pharmacological, rehabilitative, or surgical—benefit which patients without risking hearing.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Postgraduate Medicine · 1989 · 8 citations
The dizzy patient
AbstractDizziness can generally be divided into true vertigo and pseudovertigo (giddiness or light-headedness). The most common causes of pseudovertigo are hyperventilation, orthostatic hypotension, and multisensory deficits of older patients. Of the many types of true vertigo, only a few are caused by serious structural disorders of the brainstem, and these can usually be recognized by their temporal profile and concomitant symptoms and signs. Most cases of vertigo are caused by peripheral vestibular disorders that are self-limiting. Treatment is directed toward control of the acute autonomic symptoms and labyrinthine suppression until physiologic compensation takes place. Patients with vertigo that is prolonged, chronic, and recurrent may be helped by exercises designed to hasten or assist recovery of compensatory mechanisms.
The Journal of International Advanced Otology · 2019 · 7 citations · open access
The Clinical Benefit of Device Therapy for Meniere’s Disease in Adults: Systematic Review and Meta-Analysis
AbstractOBJECTIVES: This study aimed to assess the clinical benefit of device therapy on controlling the symptoms of Meniere's disease (MD). MATERIALS AND METHODS: We searched PubMed, Embase, the Cochrane Library, China National Knowledge Internet, and Wanfang Data before January 13, 2018. We selected randomized controlled clinical trials, case-controlled studies, and cohort studies that dealt with outcomes of device therapy for the treatment of MD. RESULTS: Sixteen trials met our inclusion criteria. The use of device therapy resulted in improved vertigo control, which was described as a reduction in the number of vertigo days by month (weighted mean difference [WMD]: 3.15, 95% confidence interval [CI]: 2.00-4.31), in the number of vertigo episodes by month (WMD: 7.37, 95% CI: 2.40-12.35), and in the vertigo visual analog score (WMD: 41.51, 95% CI: 34.68-48.34). In addition, the overall complete vertigo control (class A) rate was 50% (95% CI: 37%-64%). The device therapy also reduced the number of sick days by month (WMD: 4.56, 95% CI: 2.15-6.97), and the functional level improved (WMD: 2.66, 95% CI: 2.15-3.17). The electrocochleographic parameters decreased. The device therapy proved beneficial for hearing changes (WMD: 3.19, 95% CI: 0.66-5.71). No publication bias was found in the funnel plot and the results of Egger's test. CONCLUSION: This study showed that the device therapy might reduce vertigo attacks and sick days in patients with MD. Additionally, the function level and hearing level may improve after the device therapy. In addition, the decrease in electrocochleographic parameters showed that inner ear electrophysiology improved after device therapy.
Evaluation of the Effect of Nimodipine o.d. (Extended Release) vs Nimodipine t.i.d. in the Treatment of Peripheral Vertigo
AbstractSUMMARY: Vertigo has a negative impact on quality of life; therefore, it is important to find an effective and convenient therapy that allows patients to continue their everyday tasks as soon as possible and to have a better quality of life. METHODS: There were two formulations used to assess the effectiveness in vertigo treatment from peripheral origin: nimodipine administrated three times daily (Nimotop®) 30 mg versus nimodipine AP administrated once daily (Tropocer®) 90 mg; both of them in a administrated in a prospective, randomized, double-blind, double dummy, multicenter and parallel-group study, where patients with peripheral vertigo defined as a score ≥7 on the Vertigo-Dizziness Differential Diagnosis Score were included. The patients were evaluated by vertigo severity index and vestibular disability index. RESULTS: In the AP nimodipine group (NAP), vertigo severity index was decreased by 50%: 24% of patients in 14 days, 41% in 4 weeks and 89% in 8 weeks. The vestibular disability index was decreased by 50%: 24% of patients in 15 days, 83% in 4 weeks and 92% of patients in 8 weeks. In the conventional nimodipine group (NC), rate of vertigo severity was decreased by 50%: 17% of patients in 14 days, 41% of patients in 4 weeks and 90% of patients in 8 weeks. The vestibular disability index was decreased by 50%: 15 days in 17% of patients, 53% in 4 weeks and 64% in 8 weeks, without difference between groups. CONCLUSIONS: both products were effective and well tolerated in the treatment of peripheral vertigo.
Ocena skuteczności leczenia chorych z zawrotami głowy typu mieszanego za pomocą rehabilitacji ruchowej
AbstractINTRODUCTION: The aim of this work was to evaluate the efficiency of kinesitherapy in the patients with mixed-type vertigo. MATERIAL AND METHODS: The study was conducted on a randomized group of 35 patients, 21 women and 14 men aged 24-75 years (mean age 42.5 years), who were treated at the Department of Otolaryngology and Laryngological Oncology Medical University Teaching Hospital in Lodz for mixed-type vertigo. The inclusion criteria were an interview, physical and otorhinolaryngological examinations, laboratory investigations, complete audiological and otoneurological examinations, including BERA and VNG, USG examination of the blood vessels to the cranium, and CT of the cervical spine. Each patient underwent an individually selected set of habituation exercises, corrective exercises for posture and its orientation in space through 2 months. The efficiency of the implemented therapy was evaluated after two weeks, one month and two months with the use of the complete videonystagmographic test and Silvoniemi's criteria. RESULTS: The mean excitability of the labyrinths was 25.38 degrees/s before rehabilitation and 22.26 degrees/s after rehabilitation, absolute directional preponderance was 7.62 degrees/s and 1.92 degrees/s respectively, relative directional preponderance was 31.36 degrees/s and 12.57 degrees/s, and unilateral deficit 32.12 degrees/s and 14.34 degrees/s. The subjective evaluation of the vertigo intensification based on the 5 stages of Silvoniemi's scale indicates that the mean point-based evaluation reported by the patients at the beginning of the therapy was 3.85 points, whereas after the therapy was 2.91 points after two weeks, 2.35 points after one month, and 1.2 points after two months. CONCLUSIONS: Kinesitherapy is an alternative and very effective method for treating mixed-type vertigo.
IntechOpen eBooks · 2019 · 1 citations · open access
Surgical Procedures for Ménière’s Disease
AbstractThe aim of this chapter is to present a literature review on some of the main articles describing different interventions for the treatment in patients with progressive intractable Ménière disease symptoms. Even though each paper presents good results in defending its techniques, there have been few well-designed clinical studies, that is, studies involving control groups or long-term observation, in the efficacy of surgery with respect to vertigo control and hearing preservation. Focusing on presenting the different techniques established in the literature, we discuss the main indications and results obtained regarding the control of vertigo and the audiological outcomes after the procedure. Physicians should offer additional treatment strategies for Meniere’s disease patients with a long history of limiting symptoms or associated hearing loss. The surgical options for such patients should be considered carefully because surgery can damage the ipsilateral ear and the hearing function of the contralateral ear is often suboptimal. Its importance is that alternatives for treatment can only be offered to a patient when doctor knows them.
DOAJ (DOAJ: Directory of Open Access Journals) · 2025 · 0 citations · open access
Meniere’s disease: an inner ear disease caused by multiple factors
AbstractMeniere’s disease (MD) is an inner ear disorder characterized by recurrent vertigo, fluctuating hearing loss, tinnitus, and aural fullness. The pathogenesis of MD remains unclear but is closely associated with endolymphatic hydrops (EH), immune dysregulation, genetic predisposition, vascular dysfunction, and viral infection. This review summarizes recent research advances of MD pathogenesis, suggesting that MD may be a heterogeneous condition with distinct subtypes driven by different mechanisms. Future studies should integrate multi-omics analyses and animal models to elucidate its molecular pathways.
Archives of Internal Medicine · 1969 · 0 citations
Meniere's Disease.
AbstractThis book is made up of a collection of papers and discussions given at the International Symposium on Meniere's Disease, sponsored by the Mayo Clinic and Mayo Foundation. It covers etiology, pathogenesis, diagnosis, and treatment of this intriguing disease and should be especially valuable to internist, otolaryngologist, neurologist, and research worker. The bibliography is comprehensive.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
